Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority review. The French pharma group ...
Simply sign up to the Global Economy myFT Digest -- delivered directly to your inbox. The FT global inflation and interest rates tracker provides a regularly updated picture of consumer price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results